Recombinant Proteins

p53
LBP
CEA
HLA
TCL
TTC
NPM
MAF
Bax
BID

BGN Human, Sf9

Biglycan Human Recombinant, Sf9

Produced in Sf9 insect cells, BGN is a single, glycosylated polypeptide chain consisting of 340 amino acids (residues 38-368) and possessing a molecular mass of 38.3 kDa. On SDS-PAGE, its molecular size appears to be approximately 40-57 kDa. This BGN protein is engineered with a 9-amino acid His tag at its C-terminus and purified using proprietary chromatographic methods.
Shipped with Ice Packs
Cat. No.
BT27073
Source

Sf9, Insect cells.

Appearance
Clear, sterile solution without any color.

BGN Mouse

Biglycan Mouse Recombinant

Recombinant BGN, expressed in Sf9 insect cells, is a single, glycosylated polypeptide chain. This protein comprises 574 amino acids, specifically spanning from amino acid positions 38 to 369. It has a molecular mass of 64.6 kDa. However, on SDS-PAGE analysis, the apparent molecular size will appear between 50-70 kDa. The recombinant BGN is engineered to carry a 242 amino acid long hIgG-His-tag at its C-terminus. Purification of the protein is achieved using proprietary chromatographic techniques.

Shipped with Ice Packs
Cat. No.
BT27162
Source

Sf9, Insect cells.

Appearance

The product appears as a clear and colorless solution that has been sterilized by filtration.

BGN Human

Biglycan Human Recombinant

Recombinant human BGN, expressed in E. coli, is a single, non-glycosylated polypeptide chain encompassing amino acids 38 to 368. It includes a 21 amino acid His-tag at the N-terminus and has a molecular weight of 39.5 kDa. Purification is achieved through proprietary chromatographic methods.
Shipped with Ice Packs
Cat. No.
BT27007
Source
E.coli.
Appearance
Clear, colorless solution, sterile-filtered.
Definition and Classification

Biglycan is a small leucine-rich proteoglycan (SLRP) that is a key component of the extracellular matrix (ECM). It belongs to the class I family of SLRPs, which are characterized by leucine-rich repeats (LRR) and glycosaminoglycan (GAG) side chains . Biglycan is encoded by the BGN gene located on the X chromosome in humans .

Biological Properties

Key Biological Properties: Biglycan consists of a protein core with leucine-rich repeat regions and two GAG chains, typically chondroitin sulfate (CS) or dermatan sulfate (DS) .

Expression Patterns and Tissue Distribution: Biglycan is ubiquitously expressed in various ECM tissues, including bone, cartilage, and tendon . It is also found in the descending thoracic aorta, ascending aorta, right coronary artery, and other tissues .

Biological Functions

Primary Biological Functions: Biglycan plays a crucial role in scaffolding collagen fibrils and mediating cell signaling . It is involved in bone formation, muscle integrity, and synapse stability at the neuromuscular junction .

Role in Immune Responses and Pathogen Recognition: Biglycan acts as a danger signal when released from the ECM, binding to Toll-like receptors (TLR) 2 and 4, and initiating proinflammatory signaling . This links the innate to the adaptive immune response .

Modes of Action

Mechanisms with Other Molecules and Cells: Biglycan interacts with collagen, both via the core protein and GAG chains, and competes with decorin for the same binding site on collagen . It also interacts with TLR2/TLR4 and CD14 on macrophages, causing downstream activation and nuclear translocation of NF-κB .

Binding Partners and Downstream Signaling Cascades: Biglycan’s interaction with TLRs and CD14 triggers a cascade of proinflammatory signals, linking tissue stress or injury to immune responses .

Regulatory Mechanisms

Regulatory Mechanisms Controlling Expression and Activity: Biglycan expression is regulated at both transcriptional and post-translational levels. Dysregulation can lead to various clinical conditions, including metabolic disorders, inflammatory disorders, and malignancies .

Transcriptional Regulation and Post-Translational Modifications: The transcriptional regulation of biglycan involves various signaling pathways, while post-translational modifications include the addition of GAG chains .

Applications

Biomedical Research: Biglycan is studied for its role in various diseases, including cancer, where high expression is associated with tumor growth and metastasis .

Diagnostic Tools and Therapeutic Strategies: Biglycan’s presence in plasma is evaluated as a biomarker for inflammatory diseases . It is also considered a potential therapeutic target for treating inflammatory diseases and skeletal muscular dystrophies .

Role in the Life Cycle

Role Throughout the Life Cycle: Biglycan is involved in bone development and regeneration, starting from embryonic development and affecting bone integrity and strength . It also plays a role in muscle integrity and synapse stability, impacting various stages of life from development to aging and disease .

© Copyright 2024 Thebiotek. All Rights Reserved.